Recently, there have been newly developed ASO drugs for ALS and FTD in clinical trials, such as Tofersen to decrease SOD1 protein synthesis [71] and an ASO to inhibit translation of C9orf72 mRNA (WVE-004, Wave Life Sciences). This evidence concerns the gene SOD1 and frontotemporal dementia.